Loading…
Employees: 271
Size ASP Isotopes (ASPI) is a United States Health Care company (Engineering & Construction) with a market value of $318M, the 3065th largest of 3,117 United States companies the cockpit tracks. Shares closed at $2.08 on 6 Nov 2026.
Performance Over six months the shares fell 61.4%, against -21.5% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 573.4% over the last twelve months (peer median +1.8%); the operating margin is -312.3% (peer median -181.4%).
Valuation It trades at 1.02× book value against a peer median of 1.97× (4th cheapest of 16).
Price implies The share price implies a return on equity of about 20.2%; ASP Isotopes delivers -104.6%, so the price asks more than the business earns today.
Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $30.9M | $23.8M | $4.14M | $433,026 | $0 |
| Revenue growth | — | +475% | +857% | — | — |
| Gross profit | -$152,012 | $1.49M | $1.60M | $138,970 | -$72,570 |
| EBITDA | -$90.5M | -$55.3M | -$25.9M | -$16.0M | -$5.03M |
| Net income | -$132M | -$175M | -$32.3M | -$16.3M | -$4.95M |
| Free cash flow | -$83.6M | -$47.4M | -$28.1M | -$7.74M | -$7.41M |
| Capital expenditure | $15.8M | $9.65M | $11.4M | $2.33M | $4.47M |
| Total debt | $270M | $216M | $37.7M | $2.14M | $822,200 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ASPI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.7% | -8.4% | 3rd lowest of 21 |
| 6-month return | -61.4% | -21.5% | lowest of 21 |
| Return on equity | -104.6% | -78.7% | 8th lowest of 17 |
| Price / book | 1.02× | 1.97× | 4th cheapest of 16 |
| ROE the price implies | 20.2% | 18.2% | 7th most demanding of 15 |
| ROE delivered | -104.6% | -64.2% | 6th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| ASP Isotopes ASPI | United States | $318M | -61% | +573% | -105% | 1.02× | 20.2% | -104.6% |
| Galectin Therapeutics GALT | United States | $317M | +50% | n/a | n/a | n/a | n/a | n/a |
| Eikon Therapeutics EIKN | United States | $320M | -41% | n/a | -125% | 0.68× | 9.6% | n/a |
| Enanta Pharmaceuticals ENTA | United States | $320M | -28% | +1% | -70% | 3.17× | 20.8% | -70.1% |
| Orthofix Medical OFIX | United States | $321M | -32% | +3% | -14% | 0.75× | 6.9% | -13.9% |
| X4 Pharmaceuticals XFOR | United States | $315M | -28% | -52% | -113% | 1.97× | 11.4% | -113.1% |
| Ocugen OCGN | United States | $314M | -39% | -11% | -777% | n/a | n/a | n/a |
| Agenus AGEN | United States | $323M | +87% | +30% | n/a | n/a | n/a | n/a |
| Community Health Systems CYH | United States | $312M | -21% | -8% | n/a | n/a | n/a | n/a |
| Emergent BioSolutions EBS | United States | $312M | -27% | -18% | -58% | 0.99× | 16.6% | -58.2% |
| Cypherpunk Technologies CYPH | United States | $310M | +142% | n/a | -1% | 2.23× | 19.3% | -1.2% |
| Century Therapeutics IPSC | United States | $304M | -27% | -100% | -50% | 1.31× | 17.1% | -49.7% |
| Benitec Biopharma BNTC | United States | $333M | -22% | n/a | -33% | 1.85× | 9.2% | -33.2% |
| Kyverna Therapeutics KYTX | United States | $302M | -48% | n/a | -87% | 1.81× | 25.7% | -87.2% |
| CapsoVision CV | United States | $336M | -11% | +15% | -335% | 24.02× | 83.7% | -335.1% |
| Alector ALEC | United States | $340M | +9% | -83% | -385% | 8.25× | n/a | -385.1% |
| Autolus Therapeutics Plc Sponsored ADR AUTL | United States | $341M | -18% | +288% | -133% | 6.07× | 84.7% | -132.7% |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -397% | 17.67× | 84.8% | -397.3% |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -21% | 8.10× | 70.2% | -20.6% |
| ProKidney PROK | United States | $345M | -39% | +55% | n/a | n/a | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $346M | -21% | n/a | -58% | 1.69× | 12.6% | -58.1% |